

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

4

COMMUNICATE IF KNOWN	
Application Number	10/020,740
Filing Date	December 14, 2001
First Named Inventor	R.K. Bakshi et al.
Group Art Unit	To Be Assigned 1624
Examiner Name	To Be Assigned Coleman
Attorney Docket Number	19526PR

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
BC	AA	Bakshi et al., 4-aza-3-oxo-5a-androst-1-ene-17b-N-aryl-carboxamides as dual inhibitors of human type 1 and 2 steroid 5a-reductases. J. Med. Chem. 38 (1995), pp. 3189-3192 <i>duplicate</i>
BC	AB	Andriole et al., "Treatment with Finasteride Following Radical Prostatectomy for Prostate Cancer", Urology 45(3): 491-497 (1995)
BC	AC	Tsukamoto et al., "Chemoprevention of Rat Prostate Carcinogenesis by Use of Finasteride or Casodex", 87 J. Natl Cancer Inst., pp. 842-843 (1995)
BC	AD	Tolman et al., 5th Int'l Congress Hormones & Cancer Program and Abstract, Quebec City, Sept. 16-20, 1995, p.92, Abstract 48, "4-methyl-4-azasteroid 17beta(N-aryl substituted)carboxamides: Potent antiandrogenic activity with 5a-reductase inhibition"
BC	AE	Tolman et al., "4-Methyl-3-oxo-4-aza-5alpha-androst-1-en17beta-N-aryl-carboxamide: An approach to combined androgen blockade"; in press, expected to publish in March 1996 issue of J. Steroid Biochem & Molec. Bio
BC	AF	Bologna et al., "Antiandrogens and 5-alpha Reductase Inhibition of the Proliferation Rate in PC3 and DU145 Human Prostatic Cancer Cell Lines", 51(6) Curr. Ther. Res., pp. 799-813 (1992)
BC	AG	Denis, Commentary on maximal androgen blockade in prostate cancer: A theory to put into practice. Prostate 27 (1995), pp. 223-240
BC	AH	Bakshi et al., ACS Division of Medicinal Chemistry, 209th ACS Nat'l meeting Anaheim, CA, April 2-6, 1995, Abstract No. 011, "N-Phenyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamides as inhibitors of both human type 1 and type 2 5alpha-reductases"
BC	AI	Rasmusson et al., J. Med. Chem., Vol. 29, pp. 2298-2315 (1986), "Azasteroids: Structure-activity relationships for inhibition of 5alpha-reductase and of androgen receptor binding."
BC	AJ	Liang et al., Endocrinology, Vol. 117, pp. 571-579 (1985), "Species differences in prostatic steroid 5alpha-reductases of rat, dog, and human"
BC	AK	Bakshi, R.K., et al., "4-Aza-3-oxo-5a-androst-1-ene-17b-N-aryl-carboxamides as Dual Inhibitors of Human Type 1 and Type 2 Steroid 5a-Reductases. Dramatic Effect of N-Aryl Substituents on Type 1 and Type 2 5a-Reductase Inhibitory Potency.", J. Med. Chem., Vol. 38, No. 17, 1995
BC	AL	Bakshi, et al., Additions and Corrections, J. of Med. Chem., Vol. 39, No. 5, p. 1192, 1996
BC	AM	Mellin, T.N., et al., "Azasteroids as Inhibitors of Testosterone 5a-Reductase In Mammalian Skin", J. of Steroid Biochem. and Molec. Bio., Vol. 44, No. 2, pp. 121-131, 1993
BC	AN	Rasmusson, G.H., et al., "Azasteroids as Inhibitors of Rat Prostatic 5a-Reductase", J. of Med. Chem., Vol. 27, No. 12, pp. 1690-1701, 1984
BC	AO	Zheng, Jinhong, et al., Chem. Abs., Vol. 122, No. 25, 1995

Examiner Signature

Brenda Coleman

Date Considered

Nov. 21, 2003

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box

1

Approved for use through 10/31/2002. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-00), Information Disclosure Statement by Applicant
Part of Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

COMBINE IF KNOWN	
Application Number	10/020,746
Filing Date	December 14, 2001
First Named Inventor	R.K. Bakshi et al.
Group Art Unit	To Be Assigned 1624
Examiner Name	To Be Assigned Coleman
Attorney Docket Number	19526PR

OTHER NON PATENT LITERATURE DOCUMENTS

**Examiner
Signature**

Brenda Coleman

Date Considered

Nov. 21, 2003

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.